...Did everyone just panic-buy an FGF21?
Lets also not forget the strong human genetic evidence of FGF21 with both liver enzymes & triglycerides. e.g. this 2022 paper https://www.sciencedirect.com/science/article/pii/S0026049522002074
Great summary Alex. Let’s catch up when you have time.
Hi, Alex, do you think there is any regulatory risk in getting antitrust approval for the Akero acquisition? Thanks
"The efficient market hypothesis suggests that asset prices should reflect all available information"
Efficient markets or biotech, pick one bro
Yes, spot on. I recently spoke with a former big pharma CEO whose company had one of the FGF21 programs mentioned in this piece. Their account was nearly identical. “R&D was very interested in the molecule, but we never moved it forward.”
Lets also not forget the strong human genetic evidence of FGF21 with both liver enzymes & triglycerides. e.g. this 2022 paper https://www.sciencedirect.com/science/article/pii/S0026049522002074
Great summary Alex. Let’s catch up when you have time.
Hi, Alex, do you think there is any regulatory risk in getting antitrust approval for the Akero acquisition? Thanks
"The efficient market hypothesis suggests that asset prices should reflect all available information"
Efficient markets or biotech, pick one bro
Yes, spot on. I recently spoke with a former big pharma CEO whose company had one of the FGF21 programs mentioned in this piece. Their account was nearly identical. “R&D was very interested in the molecule, but we never moved it forward.”